Sterne, Kessler, Goldstein & Fox P.L.L.C.
Anti-RSPO1 antibodies
The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
OncoMed Pharmaceuticals, Inc.
A A A C A C C C C C C A C C A C G G C C C C C C G G A A C C
A61K A61K A61K C07K A61P C07K C07K C07K C07K C07K C07K A61P C07K C07K A61K C07K G01N G01N C07K C07K C07K C07K C07K C07K G01N G01N A61K A61K C07K C07K
additional inventional additional additional inventional inventional additional inventional additional additional additional inventional inventional inventional inventional inventional inventional inventional additional additional inventional inventional inventional additional inventional additional inventional inventional additional additional
Cecile Fumiko Takada Timothy Charles Austin L.
Chartier-Courtaud Axelrod Hoey Gurney